Genetron Health liver cancer screening results and
BEIJING, Oct. 28, 2021 (GLOBE NEWSWIRE) – Genetron Holdings Limited (âGenetron Healthâ or the âCompanyâ) (Nasdaq: GTH), a leading precision oncology company in China specializing in molecular profiling testing, early cancer screening products and companion diagnostics development, today announced that the clinical results and technological discoveries of its early liver cancer screening product for hepatocellular carcinoma (HCC), HCCscreen â¢, have been included in the October 2021 post of Chinese Journal of Hepatology (“the newspaper”).
The Journal was established in 1993 as a publication of the Chinese Medical Association (CMA), covering the etiology, epidemiology, pathology, immunology, pathogenesis, clinical diagnosis, and treatment and prevention of various liver diseases. This peer-reviewed monthly journal has a strong editorial board of over 50 Chinese hepatologists or specialists in related fields. It is a prestigious publication in the liver disease medical community in China and is considered to have a significant influence on the clinical practice of physicians.
Two articles related to HCCscreen â¢ were included in the last post:
- Expert consensus on the role of hematological markers in the early clinical detection of hepatocellular carcinoma (âExpert Consensusâ) – submitted by the Division of Infectious Disease Prevention and Control, China Association of Preventive Medicine (CPMA)
- Expert reviewed article on screening and monitoring for hepatocellular carcinoma in patients with chronic hepatitis B virus infection – submitted by the Chinese Foundation for the Prevention and Control of Hepatitis (CFHPC)
Written and reviewed by some 50 experts in China, including senior hepatology physicians, oncologists, epidemiologists and surgeons, both articles mentioned the revolutionary device designation for HCCscreen â¢, which was granted by Food and United States Drug Administration. In addition, Genetron Health’s ctDNA-based technological approach, which combines methylation, mutation and protein markers of HCC in its assay, as well as the results of its HIT study in 1,615 patientsÂ¹ were included.
The Expert Consensus said the HIT data showed “better screening performance than AFP plus ultrasound” and highlighted the diagnostic value of HCCscreen â¢ in identifying HCC at an early stage.
For the expert-reviewed article, the CFHPC organized relevant national experts to review domestic and foreign guidelines, combining them with the latest research findings and clinical practice experience to reach agreement. The aim was to provide a standardized reference to improve preventive control and the effectiveness of HCC screening in patients with chronic HBV infections. The article suggested that a multi-omics strategy “might offer higher sensitivity and specificity than AFP” for early detection and monitoring of HCC.
âSince our first major publication in the Proceedings of the National Academy of Sciences (PNAS) in 2019, we have made significant clinical and commercialization advances to advance HCCscreen â¢. We are delighted that our innovative approach and the results of our prospective studies have been well received by leading industry experts, âsaid Sizhen Wang, co-founder and CEO of Genetron Health. âEarly detection, especially for liver cancer, continues to be a priority for the Chinese government. Genetron Health will contribute to this initiative by developing early, accurate and easy-to-use screening tests to save more lives and reduce cancer-related costs for patients and society.
About the Chinese Journal of Hepatology
The Chinese Journal of Hepatology was established in 1993 as a publication of the Chinese Medical Association (CMA), covering the etiology, epidemiology, pathology, immunology, pathogenesis, clinical diagnosis and treatment and prevention of various liver diseases. This peer-reviewed monthly journal has a strong editorial board of over 50 Chinese hepatologists or specialists in related fields. Among them, some are academics from the Chinese Academy of Engineering. Since its inception, articles published in the Chinese Journal of Hepatology have been listed in the CD edition of the Chinese Academic Journal, China Info, Chinese Articles Database of Biological Medicine, Digestology in the World, Index Medicus, Chemical Abstracts, Chinese Science and Technology Articles in Statistical Source and Chinese Science Citation Database.
Established in 1996, the CFHPC is a national public fundraising foundation. The entity focuses on the prevention and treatment of hepatitis, and improving the overall public health in China. The foundation actively partners with other leading national and foreign government and academic organizations, including the CMA, CMPA, WHO, American Association or the Study of Liver Diseases (AASLD), etc. For more information, please visit: http://cfhpc.cn /
About the CMPA Infectious Disease Prevention and Control Division
Founded in 1987, the CPMA is a national academic and voluntary group organized by scientific and technological professionals in the fields of public health and preventive medicine. The CMPA is a direct affiliate and unit of the National Health Commission and an integral part of the China Science and Technology Association. The Division of Infectious Disease Prevention and Control was established in 2018 to focus on the prevention, diagnosis and treatment of all infectious diseases, including diseases related to the liver. For more information, please visit: http://www.cpma.org.cn/zhyfyxh/new_index.shtml
About Genetron Holdings Limited
Genetron Holdings Limited (âGenetron Healthâ or the âCompanyâ) (Nasdaq: GTH) is one of the leading precision oncology platforms in China, specializing in molecular profiling of cancer and exploiting cutting-edge technologies in biology. molecular science and data science to transform cancer treatment. The company has developed a comprehensive oncology portfolio that spans the entire spectrum of cancer management, addressing the needs and challenges of early detection, diagnosis and treatment recommendations, as well as monitoring and continuing care. disease. Genetron Health also partners with global biopharmaceutical companies to provide personalized products and services. For more information, please visit ir.genetronhealth.com.
Safe Harbor Declaration
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding clinical and marketing progress, clinical data, and the outlook for HCCscreen â¢, which involve risks and uncertainties that may cause differ significantly the actual results from the anticipated results. results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Statements that are not historical fact, including statements about the opinions and expectations of the company, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements may be identified by words or phrases such as “may”, “will”, “expect”, “anticipate”, “target”, “aim”, “estimate”, ” intend “,” “plan”, “believe”, “potential”, “continue”, “is / are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the documents filed by the Company with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required by applicable law.
Email: [email protected]
Telephone: +1 (408) 891-9255